Cancer Research Cancer Research Funding Available  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 4451-4455, December 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barthold, S. W.
Right arrow Articles by Beck, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barthold, S. W.
Right arrow Articles by Beck, D.

Modification or Early Dimethylhydrazine Carcinogenesis by Colonic Mucosal Hyperplasia1

Stephen W. Barthold2 and Deborah Beck

Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut 06510

The interaction of colonic mucosal hyperplasia with early 1,2-dimethylhydrazine (DMH) carcinogenesis was studied in random-bred NIH Swiss mice utilizing hyperplasia-inducing Citrobacter freundii. Mice inoculated with this bacterium developed significantly more DMH focal atypia than did mice without hyperplasia following a single dose of DMH (20 mg/kg). Mice with hyperplasia also developed DMH focal atypia with diminished doses of DMH (10 and 5 mg/kg), while normal mice did not. The effect of C. freundii on early DMH carcinogenesis was shown to be due to the hyperplasia rather than to a direct interaction of the bacterium with DMH. Focal atypia arose in high incidence 1 month after a single dose of DMH (20 mg/kg) but did not appear to progress to later stages of neoplasia, since significantly fewer atypia were present at 2 to 4 months among a randomized population. Colonic focal atypia may represent a reversible preneoplastic or precursor lesion as seen in other tissues, with features more aligned to neoplasia than to hyperplasia.

1 Supported by National Large Bowel Cancer Project USPHS Research Grant CA15405 from the National Cancer Institute.

2 To whom requests for reprints should be addressed.

Received 4/28/80. Accepted 8/20/80.




This article has been cited by other articles:


Home page
Infect. Immun.Home page
D. Borenshtein, P. R. Nambiar, E. B. Groff, J. G. Fox, and D. B. Schauer
Development of Fatal Colitis in FVB Mice Infected with Citrobacter rodentium
Infect. Immun., July 1, 2007; 75(7): 3271 - 3281.
[Abstract] [Full Text] [PDF]


Home page
Vet PatholHome page
C. Brayton, M. Justice, and C. A. Montgomery
Evaluating Mutant Mice: Anatomic Pathology
Vet. Pathol., January 1, 2001; 38(1): 1 - 19.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
A Konstantinidis, J. Smulow, and C Sonnenschein
Tumorigenesis at a predetermined oral site after one intraperitoneal injection of N-nitroso-N-methylurea
Science, June 11, 1982; 216(4551): 1235 - 1237.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.